Type 2 Diabetes Clinical Trial
— RewCravOfficial title:
Effects of Processed Meat on Brain Regions Related to Reward and Craving in Patients With Type 2 Diabetes, Obese Subjects and Healthy Controls
Verified date | March 2018 |
Source | Institute for Clinical and Experimental Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to
1. Compare effects of two isocaloric meals (processed meat hamburger vs. vegetarian
sandwich) in response to the postprandial period by using functional brain imaging of
reward circuitry implicated in food motivation and energy balance in patients with type
2 diabetes (T2D), obese subjects and healthy controls.
2. Characterize some of the pathophysiological mechanisms of action of different meals in
obese and T2D subjects vs. in healthy controls (serum concentrations of glucose, FFA,
IRI, C-peptide, gastrointestinal hormones, oxidative stress markers)
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 30 Years to 70 Years |
Eligibility |
Inclusion Criteria: Inclusion criteria for T2D: 1. Type 2 diabetes mellitus for at least one year 2. Treatment of T2D: diet or oral antidiabetic agents (stable drug therapy at least 3 month before the trial 3. The presence of metabolic syndrome - any three of the following symptoms: - Abdominal obesity - waist circumf. in men> 102 cm, in women > 88 cm - Diagnosis and treatment of type 2 diabetes or raised fasting plasma glucose level (FPG>5,6 mmol/l) - Raised blood pressure (BP): systolic BP > 130 mm Hg or diastolic BP >85 mm Hg, or treatment of previously diagnosed hypertension - Reduced HDL cholesterol in men < 1 mmol/l, in women < 1,3 mmol/l (or treatment) - Raised triglycerides > 1,7 mmol/l (or treatment) 4. HbA1c (according to IFCC) =4.2 a =10.5% 5. Men and women aged 30-70 years 6. Body Mass Index (kg/m2) in the range of 25- 45 7. The signed informed consent Exclusion Criteria: Exclusion criteria for T2D: 1. Type 1 diabetes mellitus 2. Unstable drug therapy at least 3 month before the trial 3. Treatment with Byetta or Victosa 4. Pregnancy (positive ß-HCG test), breast feeding or trying to become pregnant 5. Presence of pacemaker or other metal implant in the body (MR) 6. Alcoholism or drug use 7. Significant weight loss (more than 5% of body weight) in previous 3 months before the screening 8. Presence of other medical condition, which occurs during physical examination, laboratory tests, ECG, including pulmonary, neurological or inflammatory disease, which would be considered by the examiner to distort the consistency of data 9. Metal in the body (fMRI) |
Country | Name | City | State |
---|---|---|---|
Czechia | Institute for Clinical and Experimental Medicine | Prague | Czech Republic |
Lead Sponsor | Collaborator |
---|---|
Institute for Clinical and Experimental Medicine |
Czechia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Functional brain imaging of reward circuitry | fMRI (functional magnetic resonance imaging) of the brain pre- and postprandially simultaneously with both meal tests with the use of the modern method of arterial spin labeling (ASL) which allows quantification of the blood perfusion of the brain regions involved in craving and reward. | 24 months | |
Secondary | Serum concentrations of gastrointestinal hormones | Plasma concentrations of selected gut hormones will be measured enzymatically using standard kits | 24 months | |
Secondary | Serum concentrations of oxidative stress markers | Plasma concentrations of selected oxidative stress markers will be measured enzymatically using standard kits | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |